Mesoblast Limited (ASX:MSB) said that the Oncologic Drugs Advisory Committee of the US FDA had scheduled a meeting on 13 August 2020 for the review of data supporting MSB’s Biologics License Application for approval of RYONCIL™ (remestemcel-L) for the treatment of SR-aGVHD in children.
Moreover, RYONCIL is under Priority Review by the FDA with an action date of 30 September 2020, under the Prescription Drug User Fee Act.
Post announcement, MSB quoted at A$3.610 up by 7.761% at AEST 12:01 PM.
Which stock gained the most attention in 2019? Find out in our exclusive report on the much talked about lithium stocks which gained the most investor attention amidst the volatile and high drama electric vehicle market.
Read about the shift in the Electric Vehicle market in 2020 and the consequent focus on Lithium in our report.
Get an insight into the lithium prices and the trends. The supply glut kept the lithium prices in check. The escalated bilateral trade dispute between the United States and China significantly impacted the lithium chemical prices.
Understand the performance of mining companies. The lithium mining companies managed to sail through the turbulent white gold market by limiting the production in correspondence with the demand from the offtake partners.